Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,216 total articles
Global Ship Lease (GSL) is a contained, cash-generating charter owner of 69 containerships. With $1.92B of contracted revenue and an average remaining charter term of 2.5 years, the company looks poised to benefit from rising 2026 geopolitical frictions that favor fixed, long-term charters. We outline a long trade with an entry at $39.05, a $50.00 …
Micron sits at the center of the AI memory supercycle. With a market cap north of $426B, strong profitability (ROE ~20%), and constrained high-bandwidth memory supply, the upside to $1,000 is plausible if revenue and margins continue to scale. This is a long-term trade idea: enter at $378.6465, target $1,000, stop at $320. The trade leans on contin…
X4 Pharmaceuticals (XFOR) is a small-cap biotech with an FDA-marketed drug (mavorixafor / XOLREMDI) and a funded development program to expand that label into chronic neutropenic disorders. The company has raised meaningful capital, secured an EU commercialization partner with milestone upside, and is trading at a market cap (~$290M) that leaves ro…
New Found Gold (NFGC) is a development-stage gold company trading at about $888M market cap. Recent drill success, a sizable strategic stake from Dundee, and still-elevated short interest create an asymmetric risk/reward: a successful delivery of resource and de-risking catalysts could drive valuation toward multi-billion-dollar developer levels. T…
Pfizer is trading near the top of its 52-week range but still offers a compelling income-plus-upside trade. The combination of roughly $10.4B in annual free cash flow, a 6.3% dividend yield, modest leverage and a developing oral GLP-1 program supports a mid-term re-rating. We lay out an actionable swing trade with entry, stop and target, plus catal…
Venture Global’s development-led LNG model positions it for multi-year earnings growth as new export trains come online, but the stock is prone to sharp price swings tied to commodity cycles and headline risk. We recommend buying for a long-term growth exposure with disciplined entries and protection against short-term pumps.
Arcus reported a quarterly beat and the casdatifan program has shown enough signal to keep investors focused. The stock trades around $22.42 with a market cap near $2.8B and high short interest; that combination creates a tactical long opportunity with a clearly defined entry at $22.50, stop at $20.00 and a $26.00 target over a mid-term 45 trading …
Celsius (CELH) combines its core Celsius brand with the recently acquired Alani Nu to deliver rapid top-line expansion and improving cash generation. With revenue roughly $722 million in the most recent growth period and free cash flow above $523 million, the market cap near $12.3 billion looks reasonable if distribution and margin improvements con…
UnitedHealth ($UNH) is offering a buyable entry after a tough 2025 and recent macro/regulatory noise. The business still generates >$17B in free cash flow, sports a sub-€16 P/E on reported EPS, and trades at a reasonable EV/EBITDA of ~10.4. We upgrade to Buy with a clear entry, stop and target for a long-term trade horizon (46-180 trading days).
W&T Offshore (WTI) is a highly leveraged Gulf of Mexico producer trading at $3.10. With an enterprise value of roughly $620M, EV/EBITDA near 5.3 and a float of ~98M shares, the stock offers a volatile but actionable trade: entry at $3.10, target $4.25, stop $2.50 over a mid-term 45 trading day horizon. The setup combines a still-recovering producti…
Brink's announced a $6.6B acquisition of NCR Atleos on 02/26/2026 that management says will deliver at least 35% EPS accretion and $200M of annual cost synergies. The deal plus a $750M buyback and healthy free cash flow support a tactical long. Execution, financing and secular cash trends are the main risks. Trade plan provided across short-, mid- …
Microsoft’s Azure and OpenAI tie-up is driving enterprise spending and higher margins inside Intelligent Cloud. The company’s $2.96T market cap, $77.4B free cash flow and 30% ROE underpin a long trade: entry $398.37, target $500.00, stop $360.00 for a 180-trading-day horizon.
<p>Boston Beer (SAM) trades at a sensible multiple relative to its free cash flow and carries zero debt, giving management optionality to return capital or reinvest behind growth. Recent new-product momentum from Dogfish Head and improving margins combined with $215.6M in trailing free cash flow support a case for upside to $260 over the next 180 t…
Starz Entertainment has turned a recent operational pivot — prioritizing U.S. subscriber growth and mix improvements — into clearer profitability and cash generation. With adjusted OIBDA reported to have more than doubled and free cash flow of $33.3M against a market cap near $190M, the setup favors a mid-term long trade. We upgrade the rating and …
Amazon pulled back after a heavy-capex shock and sector-wide AI selling. Fundamentals remain solid: AWS growth is accelerating, 2025 revenue and EPS showed healthy gains, and valuation looks reasonable relative to profitable growth. This is a structured long trade with a $205 entry, $240 target and $195 stop — horizon ~180 trading days.
Kymera (KYMR) combines a late-stage catalyst calendar (Phase 2b for KT-621, Phase 1 start for KT-579) with a strong balance sheet ($1.6B cash, runway into 2029). The stock is trading near $90 and technicals show bullish momentum, but the story is binary: positive clinical readthroughs could re-rate the stock; setbacks could send it sharply lower. W…
Novo Nordisk has been sold off aggressively after a wave of headlines about price cuts, mixed trial news and increased competition. The panic has pushed the stock to a $169B market cap and a PE of 10.8 while the business still controls scale advantages in GLP-1 manufacturing and a pipeline geared to oral formulations. This trade idea outlines a tac…
GE Aerospace is trading near $345.72 on a steady uptrend supported by a large installed base, recurring service revenue, recent commercial and defense wins, and solid free cash flow. The company looks buyable as a trade on pullbacks, with an entry at $345.72, a conservative target of $380.00 and a stop at $320.00 for a long-term horizon (180 tradin…
Chicago Atlantic BDC is trading at what appears to be a meaningful discount to NAV amid portfolio diversification into higher-quality, senior-secured loans and a steady yield profile. With limited up-to-date market snapshots available in this note, this trade leans on BDC mechanics, distribution characteristics, and the plausibility of a discount c…
Workday reported solid Q4 results but offered cautious guidance and is being repriced by the market for AI and SaaS risk. After reworking my assumptions, I lower my fair value estimate and initiate a tactical short with a mid-term horizon: entry $134.00, target $100.00, stop $155.00. Fundamentals — high multiples, modest growth, and a stretched P/E…
Northern Oil and Gas (NOG) trades like a mid-cap energy company priced for conservative growth while producing cash and paying a 6.4% yield. Low EV/EBITDA, meaningful free cash flow, rising analyst targets and a sizeable short base create a favorable risk/reward for a long trade into the next 180 trading days.
Nebius is scaling GPU-heavy data center capacity to capture an exploding AI compute market. The company's $20+ billion backlog, a reported $3 billion Meta contract and analyst forecasts that revenue could jump from $530M in 2025 to multi-billion in 2026 justify a constructive stance. This is a directional long trade: entry $90.98, target $140.00, s…
Humana looks attractively priced after a sharp sector-driven selloff. The stock trades near $187 with a P/E around 17.8 and a market cap near $22.6B, while the business maintains strong Medicare Advantage enrollment and a growing CenterWell services unit. This trade targets a patient long-term recovery over 180 trading days with a clear entry, stop…
Broadridge (BR) has been punished alongside high-valuation SaaS names despite steady recurring revenue, solid free cash flow of $1.3186B, and strategic M&A that expands its trading footprint. We view the recent weakness as a buying opportunity: entry at $186.48, stop loss $173.00, and target $215.00 for a mid-term swing (45 trading days) with a fav…
Nike is trading at $60.995 after a painful multi-year reset. The 'win-now' push from management — product innovation, discipline in wholesale, and margin repair — creates a tactical long opportunity. Entry $60.995, target $78.00, stop $55.00, horizon: long term (180 trading days).
